These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 468886)

  • 1. [Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].
    Voelcker G; Haeglsperger R; Hohorst HJ
    J Cancer Res Clin Oncol; 1979 Apr; 93(3):233-40. PubMed ID: 468886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.
    Wagner T; Heydrich D; Jork T; Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1981; 100(1):95-104. PubMed ID: 7240346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
    Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
    Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.
    Przybylski M; Ringsdorf H; Lenssen U; Peter G; Voelcker G; Wagner T; Hohorst HJ
    Biomed Mass Spectrom; 1977 Aug; 4(4):209-15. PubMed ID: 912018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice.
    Struck RF; McCain DM; Tendian SW; Tillery KH
    Cancer Chemother Pharmacol; 1997; 40(1):57-9. PubMed ID: 9137530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
    Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
    Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys.
    Arndt CA; Balis FM; McCully CL; Colvin OM; Poplack DG
    Cancer Res; 1988 Apr; 48(8):2113-5. PubMed ID: 3349482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
    Blomgren H; Hallström M
    Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification.
    Ludeman SM; Shulman-Roskes EM; Wong KK; Han SY; Anderson LW; Strong JM; Colvin OM
    J Pharm Sci; 1995 Apr; 84(4):393-8. PubMed ID: 7629726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].
    Norpoth K; Müller G; Raidt H
    Arzneimittelforschung; 1976; 26(7):1376-7. PubMed ID: 1036928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
    Kohn FR; Sladek NE
    Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.
    Hansen RJ; Ludeman SM; Paikoff SJ; Pegg AE; Dolan ME
    DNA Repair (Amst); 2007 Aug; 6(8):1145-54. PubMed ID: 17485251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
    Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
    Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
    Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
    Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
    Voelcker G; Haeglsperger R
    Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.
    Sladek NE; Smith PC; Bratt PM; Low JE; Powers JF; Borch RF; Coveney JR
    Cancer Treat Rep; 1982 Nov; 66(11):1889-1900. PubMed ID: 7139634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.